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Abstract Post-transplant lymphoproliferative disease (PTLD)
emerged in the mid-1990s as a major graft- and life-threatening
complication of pediatric kidney transplantation. This condi-
tion, usually involving uncontrolled B lymphocyte prolifera-
tion, straddles the border between infection and malignancy,
since Epstein–Barr virus (EBV) is intimately associated with
the pathogenesis. PTLD is seenmore in younger children (more
likely to be EBV seronegative), Caucasian race, and in asso-
ciation with the more potent immunosuppression drugs. The
clinical presentation typically involves multiple enlarged lymph
nodes but varies based on localization of the lymphadenopathy.
The diagnosis is based primarily on histopathological features.
Treatment strategies include reduction of immunosuppression,
use of anti-B cell antibodies, infusion of EBV-specific cytotoxic
T lymphocytes, and chemotherapy. Many different strategies
have been tried to prevent PTLD, ranging from serial EBV viral
load monitoring and pre-emptive immunosuppression reduc-
tion to anti-viral prophylaxis. None of the major treatment or
prevention strategies has been subject to randomized clinical
trials, so their relative efficacy is still unknown. PTLD remains
a risk factor for graft loss, though re-transplants have not, to
date, been associated with repeat PTLD.
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PTLD Post-transplant lymphoproliferative disease
EBV Epstein–Barr virus
CMV Cytomegalovirus
PCR Polymerase chain reaction
CsA Cyclosporine A
CTL Cytotoxic T lymphocytes
Introduction
PTLD is a major graft- and life-threatening complication of
solid organ transplantation. This condition is best defined as
an uncontrolled proliferation of lymphocytes within the con-
text of post-transplant immunosuppression. In children, most
of the proliferating lymphocytes are of B cell lineage and are
driven by Epstein–Barr virus infection [1]. Sometimes, the
proliferations are reversible by reduction of immunosuppres-
sion, thus distinguishing PTLD from true malignancy. At
other times the severe forms of PTLD are indistinguishable
from frank lymphoma. Previously thought to be rare in
children receiving kidney transplants, the cumulative inci-
dence of PTLD in this population kept rising through the
mid-1990s and early part of this decade [2]. The emergence
of Epstein–Barr virus (EBV)–PTLD was part of a sequence
of emerging viral infections in transplantation, starting with
cytomegalovirus (CMV), followed by EBV and later fol-
lowed by BK virus. This teaching article focuses on PTLD
after pediatric kidney transplantation. Several excellent re-
views have covered PTLD across different organ and tissue
transplants [1, 3–8].
Pathophysiology
The pathophysiology of PTLD has been described [1, 4, 8].
EBV is a DNA virus of the gamma herpes family. Most
immunocompetent individuals acquire subclinical infection
at some point prior to adulthood. The virus establishes a
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long-lived latency in reticuloendothelial cells, similar to
another herpes virus cytomegalovirus. B lymphocytes are
an important reservoir for EBV. Left unchecked, the virus
will insert its own genome into the B cell and induce un-
controlled B cell proliferation. However, immunocompetent
individuals can keep the infected B cells in check through
EBV-specific CD8+ cytotoxic T lymphocytes (CTLs). When
transplant recipients receive immunosuppression to prevent
rejection, an important consequence of such non-specific
immunosuppression is the inhibition of the EBV-specific
CTLs. Thus, in this setting, EBV-infected B cells may prolif-
erate unchecked. This proliferation is particularly marked
when the transplant recipient is EBV seronaive and acquires
a primary infection when immunosuppressed.
Epidemiology of PTLD
The highest risk of PTLD is in the EBV seronegative re-
cipient who receives a kidney allograft from an EBV sero-
positive donor. Multiple studies have shown that the risk of
PTLD in such cases is increased threefold to 24-fold [5, 9–
13]. CMV co-infection can further add to the risk [13].
PTLD rates vary with the organ transplanted. Thoracic
(heart, lung or combined) and intestinal transplants have the
highest rates of PTLD, typically in the 5–10% range [5,
14]. Pediatric kidney transplants were previously associated
with PTLD rates of < 1%, but these rates have climbed and
are now in the 2–4% range at 3–5 years after transplanta-
tion [2, 14, 15]. Prospective studies have mirrored this
trend. The IN01 study was the first National Institutes of
Health (NIH)-sponsored multi-centered clinical trial in
pediatric kidney transplantation in the USA, conducted
between 1994 and 1999. In that study, the PTLD rates were
3.4% in the OKT3 induction arm and 2.1% in the cyclos-
porine A (CsA) induction arm, with a mean follow-up time
of 44 months for all study participants [16]. In contrast, the
next NIH-sponsored study, the SW01 trial of steroid
withdrawal in pediatric kidney transplant recipients con-
ducted between 1999 and 2004, had an overall PTLD rate
of 6% in both arms, leading to early termination of that
study [17]. In comparison to kidney allografts, PTLD rates
are 8% by 5 years after transplantation in the Pediatric
Heart Transplant Study [5]. The most recent national data
from pediatric liver transplants, from the United Network
for Organ Sharing (UNOS) and SPLIT liver transplant
registries, indicate a 2.4% cumulative incidence of PTLD
[14].
PTLD was very rare in the days of two-drug immunosup-
pression after transplantation using azathioprine and orally
administered steroids. Reports of PTLD started increasing
after the introduction of cyclosporine A and then other newer
immunosuppressive agents, such as induction antibodies. In
general, the higher the “total intensity” of immunosuppres-
sion, the higher the risk for PTLD. Individual drugs may or
may not increase the risk. For most of the typically used drugs,
small single center studies cannot accumulate large enough
samples to delineate a higher risk fully. In contrast, large
registry databases, especially in the United States of America,
can evaluate large samples but do not have EBV information,
and the quality and completeness of the data are inferior to
single center information. Thus, both types of studies involve
a trade-off. As such, CsA, OKT3, rabbit anti-thymocyte glob-
ulin, basiliximab and daclizumab have all been associated
with higher PTLD risk in at least one study [13, 18, 19],
though, for each drug, there are also studies documenting no
higher risk [20–22]. Cyclosporine was compared to tacroli-
mus by the Cochrane Review Group, and no significant
differences in relative risk for PTLD were found in this meta-
analysis of 30 different prospective trials [23]. Mycopheno-
late mofetil has not been associated with higher PTLD risk to
date [2] but has been associated with higher risk for CMV
and BK virus infections [24]. Sirolimus has shown some
anti-EBV effects in vitro [25, 26], and a large registry study
suggested lower incidence of malignancy with early use of
mammalian target of rapamycin (mTOR) inhibitor [27].
Pathology
PTLD lesions can range from mild lymphoid hyperplasia to
frank lymphoma, with several grades in between [28]. Most
lesions are either polymorphic or monomorphic. Additional
classifications based on clonality are available, dividing
lesions into polyclonal and monoclonal, the latter consid-
ered more severe. EBV staining via Epstein Barr early RNA
(EBER) and latent membrane protein (LMP) help us to de-
termine if the tumor cells contain EBV. CD20 staining of the
lymphocytes helps us to decide if anti-CD20 antibody therapy
will be useful.
Clinical features
PTLD can present in a variety of ways, so a high index of
suspicion must be maintained at all times [29]. The most
common presentation is with lymph node enlargement,
either in easily visible sites (such as cervical) or internal
sites not immediately visible. In the latter case the
symptoms are related to whichever internal structures have
been compressed or impaired in function. Internal areas of
presentation include the gut, bone marrow or central ner-
vous system. Mass effects in these areas can present as
vomiting/diarrhea, hematological cytopenias, or symptoms
of brain tumors. The latter has the worst prognosis amongst
all presentations. From North American Pediatric Renal
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Transplant Cooperative Study (NAPRTCS) data, lymph
node involvement was the most common presentation,
followed by abdomen, kidney allograft and central nervous
system (Table 1). PTLD can involve the allograft itself and
may rarely present as fever with no localizing features.
In children receiving kidney transplants, unlike in adults,
most cases of PTLD occur in the first year after trans-
plantation, when immunosuppression is most intense and
chances of EBV primary infection are higher in the D+/R-
mismatch. Early PTLD cases are almost always likely to be
EBV-driven and of B cell lineage. The majority of late PTLD
cases are also EBV driven and of B cell lineage, but the
proportion of non-EBV or T cell PTLD is higher in late
PTLDs. In addition to central nervous system involvement,
other poor prognostic factors include monoclonal lesions,
OKT3 use, elevated lactate dehydrogenase levels, and high
tumor staging scores [30–34].
Diagnosis
The diagnosis is essentially based on histopathology, so a
tissue specimen is usually needed. High peripheral blood
EBV polymerase chain reaction (PCR) loads can support a
diagnosis of EBV-PTLD but are not diagnostic themselves.
Similarly, imaging techniques such as computed tomogra-
phy (CT) or positron emission tomography (PET) [35] can
help localize and stage the tumor but are not diagnostic.
Oncologists can help with this staging. The differential
diagnosis can include Bartonella infection [36], tuberculosis
or reactive lymphadenopathy. EBV serology and monospot
tests are not useful for diagnosis in the transplant setting.
Treatment
Most physicians will first reduce immunosuppression once
PTLD has been diagnosed. However, there is no consensus on
how to reduce immunosuppression or which drugs to target
first. A commonly used approach is to reduce calcineurin
inhibitors to half their dose or target level and discontinue
anti-metabolite agents, while continuing oral steroid treatment
[37]. This strategy is revaluated quickly, usually within 1–
4 weeks, to determine if additional interventions are needed.
Such revaluations should include clinical reassessment, EBV
PCR response if initial load was high, and may also include
follow-up imaging if needed. In cases of severe, dissem-
inated disease, discontinuation of all immunosuppression,
with the exception of steroids, has been tried. Anti-CD20
monoclonal antibody therapy (rituximab) is now widely ac-
cepted as the second line therapy in CD20-positive lesions
[38, 39]. Alpha interferon was used previously but has been
replaced by rituximab. For more severe lesions or those that
do not respond, chemotherapy with protocols used for non-
Hodgkin’s lymphoma is employed, in conjunction with on-
cologists. Some protocols in common use will lower the
dose of cyclophosphamide or combine low-dose cyclophos-
phamide and steroids with rituximab [40, 41]. Each of these
strategies has a moderately high success rate in the appro-
priate situation, but no strategy is associated with 100%
complete remission. There are no head-to-head randomized
comparison trials to judge which therapy is more efficacious.
Many centers will also use anti-viral agents concomitant
with the above interventions. Typically, ganciclovir or val-
ganciclovir are employed for this purpose, since these drugs
are much more potent against EBV than acyclovir. The use
of these drugs to treat or even prevent PTLD, though
widespread, is considered controversial, since they affect
only replicating viruses. In PTLD, most of the viral genome
is in non-replicative phase, with EBV DNA copies being
generated by replicating infected B cells.
Other interventions
Owing to the potential serious impact of graft loss or pa-
tient death that can occur with PTLD, many investigators
have attempted immunosuppression minimization as part of
a broader attempt to reduce the frequency of post-trans-
plantation infections, including BK virus nephropathy,
CMV infection and transplant pyelonephritis. Such mini-
mization can involve any of several strategies, such as
calcineurin inhibitor dose and target level reduction, avoid-
ance of induction antibody, and avoidance of steroids or
anti-metabolites [42, 43]. Some interventions could be
implemented in “pre-emptive” fashion, as discussed below.
Prevention
Preventing PTLD is far more preferable to having to treat
established disease. Primary prevention could be achieved
by immunizing children against EBV prior to their becoming
immunosuppressed. A vaccine developed against the gp350
Table 1 Distribution of PTLD by anatomic location in pediatric
kidney transplant recipients (data from NAPRTCS)




Central nervous system 11
Other 16
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envelope glycoprotein is currently in phase I/II clinical trials
in the UK [7].
Secondary prevention has been tried by several inves-
tigators, using either serial peripheral blood EBV PCR
monitoring or immune function monitoring. When EBV
loads are seen to rise, immunosuppression drug levels are
reduced, or specific drugs are discontinued, to reduce the
total intensity of immunosuppression. However, in children,
not all rises in EBV viral load necessarily lead to PTLD.
Some children may develop a chronic high load carrier state
[44], so the efficacy of this strategy is still not fully defined.
Another form of secondary prevention is the use of anti-
viral prophylaxis. The use of anti-viral agents has been
discussed in the treatment section. As with treatment, use of
anti-viral agents in prevention is also controversial, since
the drugs do not prevent viremia from B cell proliferation.
Both serial EBV monitoring and anti-viral prophylaxis have
been associated with reduced incidence of PTLD, albeit in
studies that were not randomized or prospective in nature.
Outcomes
Though many cases of PTLD respond to therapy, some do
not. The most recent data from a large pediatric kidney
transplant multi-center trial suggest that there is an improved
prognosis compared to the prognosis before [17]. Neverthe-
less, data from NAPRTCS indicate that the risk of graft loss
is clearly higher after PTLD has occurred. The optimum time
to restart high-dose immunosuppression is not known. For
organs such as heart and lung, graft dysfunction or rejection
can be immediately life-threatening. If graft loss has occurred,
PTLD has not been reported so far in the re-transplants [45].
Questions (Answers appear after the reference list)
(1) Which of the following interventions is not a preventive
strategy for PTLD?
a. Reduction of immunosuppression
b. Anti-viral agent usage
c. Cyclophosphamide usage
d. Serial peripheral blood EBV PCR monitoring
(2) Which of the following interventions is not a treatment
strategy for PTLD?
a. Reduction of immunosuppression
b. Anti-viral agent usage
c. Cyclophosphamide usage
d. Serial peripheral blood EBV PCR monitoring
(3) Which area of involvement with PTLD is associated
with the worst prognosis?
a. Allograft involvement
b. Lymph node involvement
c. Central nervous system involvement
d. Bone marrow involvement
(4) The following are risk factors for the development of
PTLD except
a. Caucasian race
b. Recipient is seronegative for EBV at the time of
transplant
c. Development of CMV disease
d. Use of mycophenolate mofetil (MMF)




c. BK virus infection
d. Urinary tract infection
(6) In an immunocompetent host, the regulation and
control of proliferation of the EBV-infected B cells
occur primarily by means of
a. Plasma cells
b. Phagocytes (neutrophils, macrophages, dendritic
cells)
c. Cytotoxic T cells
d. The complement system
(7) In pediatric kidney transplant recipients most cases of
PTLD are observed
a. Within the first year of transplantation
b. Between the first and second year after
transplantation
c. Five years after transplantation
d. Immediately after treatment for acute rejection
(8) All of the following statements are true, except
a. EBV viral loads may be elevated in the absence of
clinical evidence of EBV disease or PTLD
b. EBV PCR is a useful screening test with high
specificity for EBV disease and can replace histo-
logic examination when the diagnosis of PTLD is
considered
c. Immunosuppressive agents may result in false nega-
tive results of EBV serologic tests, even at the time
of active EBV disease
d. Not every patient with PTLD will have elevated
EBV viral loads
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1) Answer: c Rationale: cyclophosphamide is used as a component of
the CHOP protocol of chemotherapy (cyclophosphamide,
hydroxydaunorubicin, vincristine, and prednisone) for
advanced PTLD, but not as prophylaxis. Reduction of
immunosuppression and anti-viral agents can be used as
either prevention or treatment strategies.
2) Answer: d Rationale: serial EBV PCR monitoring can be used to
detect high viral loads prior to PTLD development and
can potentially be used to monitor treatment efficacy,
but it is not a treatment intervention itself.
3) Answer: c Rationale: central nervous system involvement has
consistently been associated with the worst prognosis
across different types of organ transplants. Allograft
involvement is associated with a good prognosis in
kidney transplants, though the prognosis is not as good
when allograft failure is directly life-threatening, as in
thoracic organ transplants.
4) Answer: d Rationale: male gender and Caucasian race have been
found to be risk factors for PTLD. In general, the higher
the burden of immunosuppression, the higher the risk
for PTLD. However, MMF has not been associated
with higher PTLD risk, though it has been associated
with higher risk of CMV and BK virus infection.
5) Answer: a Rationale: EBV has been intimately linked to PTLD by
epidemiologic, molecular and immunostaining analyses.
CMV may be a co-factor, while urinary tract infection
(UTI) and BK virus infection have not been associated
with PTLD.
6) Answer: c Rationale: cellular immunity is thought to be more
important in the control of proliferating infected B cells
through EBV-specific cytotoxic T lymphocytes.
7) Answer: a Rationale: PTLD occurs more commonly within the first
year of transplantation in children receiving kidney
transplants, when more intense immunosuppression is
used and EBV primary infection is more likely in a
donor positive/recipient negative mismatch.
8) Answer: b Rationale: EBV viral loads may be elevated in the
absence of PTLD and should not replace histologic
examination of suspected sites of PTLD involvement.
Answers
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